Wave Life Sciences, Inc.
Moat Score — Wave Life Sciences, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Proprietary PRISM stereopure oligonucleotide chemistry platform and a patent portfolio extending to 2045 provide meaningful, hard-to-replicate IP, though a disclosed Singapore Patents Act filing issue introduces some uncertainty. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | No commercial manufacturing scale or cost advantage yet; the in-house GMP facility supports clinical supply but offers no demonstrated cost edge over competitors. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | Pre-commercial clinical-stage company with no approved products generating revenue, so no pricing power exists today. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | No network effects; therapeutic value to one patient or partner does not increase with additional users. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Minimal current switching costs given no marketed product, though the GSK collaboration's multi-year milestone structure creates some partner-side commitment. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | A multi-modality chemistry platform capable of producing several drug candidates from one core technology provides some scale efficiency in R&D, but clinical-stage biotech economics remain inherently capital-intensive and unscaled. |